Posters - NCDEU: An Annual Meeting Sponsored by ASCP
Posters - NCDEU: An Annual Meeting Sponsored by ASCP
Posters - NCDEU: An Annual Meeting Sponsored by ASCP
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Pharmaceutical Pipeline Session<br />
Tuesday, May 29, 2012<br />
1:00 pm – 3:00 pm *Pharmaceutical Pipeline Session<br />
Frank Lloyd Wright Salon E-F<br />
Chair: Carlos Zarate, M.D., National Institute of Mental Health<br />
2012 Program Committee Co-Chair<br />
1:00 pm – 1:15 pm PNB02 : A Beneficial Treatment for Insufficient<br />
Response with Single Agent Treatment in<br />
Schizophrenia?<br />
Erik Buntinx, Ph.D., PharmaNeuroBoost NV<br />
1:15 pm – 1:30 pm Novel Dopamine Stabilizer<br />
Marc Cantillon, M.D., Reviva<br />
1:30 pm – 1:45 pm NOP Agonism: A Novel Mechanism for the<br />
Treatment of <strong>An</strong>xiety and Depression<br />
Carla M. Canuso, M.D., Janssen Research &<br />
Development, LLC<br />
1:45 pm – 2:00 pm Early Clinical Development of the Opioid<br />
Modulator ALKS 5461 in the Treatment of<br />
Depression and Addiction<br />
Elliot W. Ehrich, M.D., Alkermes<br />
2:00 pm – 2:15 pm Clinical Development of the Norepinephrine<br />
Reuptake Inhibitor Edivoxetine (LY2216684 HCl)<br />
for the Treatment of Major Depressive Disorder:<br />
Use of Pharmacokinetics, Pharmacodynamics and<br />
Biomarkers<br />
William Kielbasa, Ph.D., Eli Lilly and Company<br />
2:15 pm – 2:30 pm Merck Neuroscience Pharmaceutical Pipeline:<br />
June 2012<br />
Armin Szegedi, M.D., Ph.D., Merck Research<br />
Laboratories<br />
2:30 pm – 2:45 pm A Novel V1a Receptor <strong>An</strong>tagonist and Potential<br />
<strong>An</strong>tidepressant, SRX246, Blocks Vasopressin<br />
Mediated Effects on Stress & Fear: <strong>An</strong> fMRI Study<br />
Neal G. Simon, Ph.D., Azevan Pharmaceuticals,<br />
Lehigh University<br />
*of special interest to clinicians<br />
32
Change language